ArticleFaraday discussions2021
Interactions of polymyxin B with lipopolysaccharide-containing membranes.
Article in Faraday discussions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinical outcomes and adverse events associated with intravenous polymyxin-containing therapy in hospitalized children with resistant Gram-negative infections: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Pooled it
- A 6His-2Flag dual-tag strategy enables high-yield production of antimicrobial peptide N6 inSynthetic and systems biotechnology · 2027Article
- Antimicrobial effects of novel Hermetia illucens peptides.Scientific reports · 2026Article
- Molecular Interactions of Fluoroquinolone Antibiotics with Lipid Membranes.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- The Potential of Non-Ribosomal Peptide Engineering for Creating New Antimicrobial Complexes.Molecules (Basel, Switzerland) · 2026Review
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Comparative Effectiveness of Colistin Sodium versus Polymyxin B Sulfate Against CR-GNB: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Modulation of LPS-associated virulence activity for reduction of periodontal inflammatory burden.Frontiers in microbiology · 2026Article
- Polymyxin resistance in Gram-negative bacteria: a comprehensive review with a focus on the role of 4-amino-4-doexy-L-arabinose.Molecular biology reports · 2025Review
- Polymyxin B lethality requires energy-dependent outer membrane disruption.Nature microbiology · 2025Article
- Antibacterial activity of eravacycline againstMicrobiology spectrum · 2025Article
- Pharmacological Potential of Coriander Seeds: A Dual Action Agent Against LPS ofIndian journal of microbiology · 2025Article
- Specific labeling of outer membrane vesicles with antibiotic-conjugated probe reveals early bacterial infections in blood.Nature communications · 2025Article
- Extracellular NCOA4 is a mediator of septic death by activating the AGER-NFKB pathway.Autophagy · 2024Article
- Exploring the Synergy between Nano-Formulated Linezolid and Polymyxin B as a Gram-Negative Effective Antibiotic Delivery System Based on Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2024Article
- Integration of (S)-2,3-oxidosqualene enables E. coli to become Iron Man E. coli with improved overall tolerance.Biotechnology for biofuels and bioproducts · 2023Article
- Polymyxin B-Modified Fosfomycin Liposomes Target Gram-Negative Bacteria and Exert Synergistic Antibacterial Effect.ACS omega · 2023Article
- Characterization of the Antimicrobial Activities ofPharmaceutics · 2023Article
- Polymyxin B inhibits pro-inflammatory effects of E. coli outer membrane vesicles whilst increasing immune cell uptake and clearance.The Journal of antibiotics · 2023Article
- Bacterial extracellular vesicles repress the vascular protective factor RNase1 in human lung endothelial cells.Cell communication and signaling : CCS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial resistance to antibiotics constantly remodels the battlefront between infections and antibiotic therapy. Polymyxin B, a cationic peptide with an anti-Gram-negative spectrum of activity is re-entering use as a last resort measure and as an adjuvant. We use fluorescence dequenching to investigate the role of the rough chemotype bacterial lipopolysaccharide from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.